Overall, these data suggest that IGFL2-AS1 is a good candidate regulator of radioresistance and indicate that the level of IGFL2-AS1 transcript could be used as a biomarker for discriminating the radioresistance of CRC. The gene discussed is IGFL2; the disease is colorectal carcinoma.